A 9-percentage-point drop in no-show rates sounds modest until you see the denominator: that figure came out of more than 90,000 scheduled visits across a subset of Velocity’s sites, translating to more than a 20% gain in screening attendance. That’s the data behind Velocity Clinical Research’s decision to roll Stitch, its patient engagement platform, out across its entire network of 70-plus sites in the United States and Europe under a new multi-year agreement.
The numbers from the pilot period are specific enough to matter operationally. Stitch supported over 25,000 participants through those 90,000-plus scheduled visits, with more than 87% of participants using the platform and completing over 17,000 feedback surveys. The two organizations ran a joint analysis to isolate Stitch’s contribution to screening attendance, controlling across protocols and therapeutic areas before reporting that 9-point no-show reduction. For sponsors managing fixed enrollment windows, fewer missed screenings means fewer replacement visits to schedule and fewer protocol deviations to explain.
The expansion does more than widen the deployment footprint. Velocity is bringing its operational data and site expertise into joint product development with Stitch, with both parties planning to test new approaches to retention and protocol compliance across the full network and publish the results. That arrangement gives Stitch something most clinical-tech vendors lack at this stage: a single, accountable site organization running more than 70 wholly owned sites across four countries, with centralized operations that can run controlled comparisons at scale rather than aggregating messy data from dozens of independent sites with different workflows.
For site networks watching this, the meaningful detail is not the partnership itself but what Velocity intends to do with the evidence it generates. Publishing performance data from a 70-plus-site network, with methodology transparent enough to show a 9-point no-show reduction, sets a bar that anecdotal engagement metrics from smaller deployments cannot easily match. Whether that published evidence changes sponsor procurement conversations around site selection is the thing worth watching.
Source link: https://velocityclinical.com/velocity-and-stitch-expand-global-partnership/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
